Intra-operative technology improves lumpectomy procedures for many breast cancer patients
the ONA take:
A recently developed, intra-operative technology aids lumpectomy procedures by detecting microscopic amounts of cancer cells on tumor tissue.
These cancer cells are not typically visible during or after routine surgery. The MarginProbe system, manufactured and marketed by Dune Medical Devices, employs radio-frequency spectroscopy technology to detect cancer cells in the outer margins of removed tissue.
Dr. Freya Schnabel, Director of Breast Surgery at NYU Langone, led a multi-institutional retrospective study that evaluated nearly 600 patients that underwent lumpectomies for non-palpable breast malignancies. Dr. Schnabel utilized the new tool on approximately 50 patients, and the researchers concluded that the use of the MarginProbe system may as much as triple the odds of discovering additional cancer on removed tissue margins, when compared to more traditional intra-operative imaging.
In cases when cancerous cells are found in the margin tissue by the MarginProbe, the surgeon can remove additional tissue to be certain no cancer remains.
The use of this new tool could help surgeons determine that all cancer cells are excised during the initial surgery, sparing patients unnecessary additional procedures.
New intra-operative technology aids lumpectomy procedures by detecting microscopic amounts of cancer cells on tumor tissue.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|